Airlift Bioreactors Market

Sartorius reported EUR 2.87 billion of Bioprocess Solutions sales for 2025 in its results release of 3 February 2026, while the gas-mixed corner of bioreactor spending is a fraction of that, at USD 721.7 million. Airlift bioreactors are culture vessels that circulate and aerate broth with rising gas through a riser and a downcomer instead of an impeller, and the Airlift Bioreactors Market covers internal-loop, external-loop, single-use and photobioreactor designs plus their controllers. Douglas Insights estimates that 9,862 airlift units shipped in 2025 at an average USD 73,180 each, so 9,862 units times USD 73,180 equals USD 721.7 million. The model reaches USD 1.31 billion by 2035, a revenue CAGR of 6.14% made of 4.35% unit growth and 1.72% price growth. The study belongs to our life science instruments coverage, and every step follows the Douglas Insights research methodology.

Which airlift bioreactor type makes the money, by segment?

Internal-loop airlift systems lead with 34.6% of 2025 revenue, or USD 249.7 million, because glass and steel draft-tube vessels remain the default for microbial and plant-cell work. Single-use airlift bag systems grow fastest, at 8.46% a year, as cell therapy and phage teams drop cleaning validation. Five product types are counted.

Internal-loop airlift systems hold USD 249.7 million because a concentric draft tube gives the most predictable circulation per litre and fits existing steam-in-place suites. Single-use airlift bag systems carry USD 164.5 million, a 22.8% share, and reach USD 370.6 million by 2035. Their 8.46% rate is the fastest in the airlift bioreactor mix: a pre-sterilised bag removes the cleaning step, which matters most in lentiviral vector, bacteriophage and stem cell runs of 1.5 L to 100 L. External-loop airlift systems take 17.3%, or USD 124.9 million, because a separate downcomer gives room for heat exchangers and gas separators on hot microbial fermentation. Airlift photobioreactors account for USD 100.3 million and 13.9%, sold mainly into microalgae cultivation for pigments, omega-3 oils and feed. Controllers, spargers and spare parts make up the remaining 11.4%, USD 82.3 million, and grow slowest at 4.13% since installed vessels last 12 to 20 years.

Which applications put airlift bioreactors into microalgae, plant-cell and phage plants?

Biopharmaceutical proteins and plant cell culture absorb about 41.7% of airlift bioreactor revenue in 2025, Douglas Insights calculates, because gentle bubble mixing keeps shear-sensitive cells intact at volumes above 400 L. Microbial fermentation adds 21.6% and microalgae cultivation 16.2% of the total.

The application split runs as follows in our model. Biopharmaceutical proteins take 27.4%, plant cell culture 14.3%, microbial fermentation 21.6%, microalgae cultivation 16.2%, cultivated meat 4.9%, wastewater treatment 9.8% and research uses 5.8%. Plant cell culture is the clearest proof case. Protalix, whose ProCellEx system expresses proteins in plant cells, holds US patent 10,364,413, granted on 30 July 2019, for a disposable bioreactor above 400 L that mixes with neither mechanical agitation nor a classic sparger. The patent specifies 55 gas inlets per square metre, aeration of 0.07 to 0.1 gas volumes per medium volume per minute and bubbles of about 300 cubic millimetres. Cultivated meat is the smallest line at 4.9% but the most watched, since airlift columns avoid the impeller damage that hampers animal cells at scale.

Why are cell therapy and plant-cell programmes behind rising airlift bioreactor demand?

Four drivers add 4.35 points of annual unit growth to airlift bioreactor shipments through 2035, Douglas Insights reckons. Single-use cell and gene therapy work leads with 1.62 points, and plant-cell protein production follows with 1.08 points, ahead of algae and lab replacement.

Single-use adoption in advanced therapies contributes 1.62 points. Viral vector, bacteriophage and stem cell teams run many small batches, often 10 L to 50 L, and a pre-sterilised airlift bag cuts the turnaround between batches to a bag swap. Our model counts 2,610 airlift systems in the 10 to 50 L band in 2025, the band where single-use designs win most often. Readers following the contract side can compare this with our Cell and Gene Therapy CDMO Services Market study, where outsourced viral vector capacity sets the pace.

Plant-cell and microbial protein production adds 1.08 points. On 10 May 2023 Protalix and Chiesi announced FDA approval of Elfabrio (pegunigalsidase alfa-iwxj), a recombinant enzyme expressed in plant-cell culture, for adults with Fabry disease. A commercial approval for a plant-cell product gives every gas-mixed disposable reactor design a regulatory reference point. Douglas Insights counts 690 production vessels of 500 to 8,000 L shipped in 2025, and plant-cell and enzyme lines buy roughly 1 in 4 of them.

Microalgae and cultivated meat add 0.94 points. Airlift photobioreactors grow at 6.21% a year, as algae producers move from open ponds to closed columns for food-grade pigments and oils. Cultivated meat pilots add a smaller, newer pull, buying columns in the 50 to 500 L band. The replacement cycle in academic and research institutes adds the last 0.71 points: about 5,140 benchtop vessels under 10 L ship each year, many replacing glassware bought 12 to 15 years earlier. Together 1.62, 1.08, 0.94 and 0.71 points give the 4.35% unit leg.

Bioprocess capital spending is also recovering. Sartorius lifted Bioprocess Solutions sales 9.5% in constant currencies to EUR 2.87 billion in 2025, its 3 February 2026 release shows, and guided group growth of 5% to 9% for 2026. Airlift vessels ride the same purchase cycle as stirred tanks, a few quarters behind it. Group sales of EUR 3.54 billion in the same release show how large the wider bioprocess pool is next to the USD 721.7 million airlift slice. Cellexus, the Dundee specialist, has pushed its single-use airlift bag range to 50 L of working volume and pursued a 100 L design for stem cell production, the scale step that turns lab buyers into pilot buyers.

Which shear, scale-up and oxygen-transfer hurdles hold airlift bioreactor sales below their potential?

Three hurdles take 1.92 points off airlift bioreactor unit growth, Douglas Insights finds: oxygen-transfer limits at high cell density remove 0.84 points, stirred-tank incumbency 0.61 points and a soft equipment cycle 0.47 points. The net airlift bioreactor unit leg is 4.35%.

Oxygen transfer is the hard ceiling. A gas-driven column without an impeller reaches lower volumetric mass-transfer rates than a stirred tank at the same gas flow, so dense CHO fed-batch processes above 20 million cells per millilitre rarely move to airlift designs. That keeps airlift bioreactors out of most monoclonal antibody suites and removes 0.84 points from unit growth.

Stirred-tank incumbency removes 0.61 points. Thermo Fisher sells DynaDrive single-use bioreactors from 5 L to 5,000 L and HyPerforma units from 50 L to 2,000 L, neither of them an airlift design, and regulatory filings are written around those platforms. Changing the mixing principle after a filing means comparability work that few biologics sponsors accept. Our Biopharmaceutical Single-Use Bioprocessing Market report sizes that wider single-use base.

A soft equipment cycle removes 0.47 points. Eppendorf’s 2025 annual report shows group revenue of EUR 924 million and an 11.5% fall in its Bioprocess unit, partly from discontinuing sterilisation-in-place (SIP) products. Without these three brakes the airlift volume leg would run near 6.27% a year, not 4.35%.

How much does an airlift bioreactor sell for, per litre of working volume?

Airlift bioreactors sold for an average USD 73,180 per unit in 2025, Douglas Insights estimates. Realised prices run from about USD 12,000 for a benchtop glass column to above USD 800,000 for an industrial steel column above 8,000 L. Price falls per litre as vessels grow.

Price per litre falls steeply with scale, roughly 100-fold from a 5 L glass column to a 20,000 L steel loop. Single-use airlift bags add a recurring cost: a 50 L bag set typically lists at USD 650 to USD 1,400, and a phage lab running 40 batches a year spends more on bags than on the controller within 3 years. The average airlift bioreactor price rises 1.72% a year to about USD 86,790 in 2035, because the mix shifts towards instrumented single-use and pilot systems, not because list prices climb fast.

Which suppliers compete with impeller vessels in the airlift bioreactor business?

The top three airlift bioreactor suppliers hold about 31.8% of 2025 revenue on Douglas Insights estimates. Sartorius, Getinge through Applikon and Eppendorf form that group, leaving a long tail of specialist builders in Scotland, Germany, Sweden, Spain and India. The share basis is disclosed segment sales.

Sartorius anchors the field with an estimated 14.6% share, built on its bioprocess sales base of EUR 2.87 billion reported on 3 February 2026 and a catalogue that spans glass, steel and single-use vessels. Getinge holds about 9.4% through Applikon Biotechnology of Delft, which it agreed to buy on 19 December 2019 for EUR 80 million in cash plus an earn-out of up to EUR 60 million; Applikon then had about 180 staff and sales of roughly SEK 450 million, per the Getinge release. Eppendorf, with about 7.8%, sells benchtop fermentation and cell culture systems into academic and research institutes.

Cellexus, based in Dundee, is the purest airlift specialist: its CellMaker single-use airlift bioreactor runs 1.5 L to 50 L working volumes across microbial, bacteriophage and mammalian cells. Thermo Fisher Scientific matters as the rival platform, since its 5 L to 5,000 L DynaDrive range sets the stirred-tank price airlift vendors must beat. Protalix is a captive user rather than a vendor, building its own disposable gas-mixed reactors. Kuhner, Solida Biotech, Bioengineering AG, Belach Bioteknik and Electrolab Biotech make up much of the remaining 68.2%.

Where do airlift bioreactor sales concentrate, region by region?

North America leads airlift bioreactor revenue with USD 277.1 million in 2025, or 38.4%, Douglas Insights puts it, while Asia Pacific grows fastest at 7.94% a year on Chinese and Indian fermentation and algae capacity. Europe follows North America with USD 214.3 million, a 29.7% share.

North America carries USD 277.1 million and reaches USD 478.7 million by 2035, at 5.62%, on cell and gene therapy pipelines and university core labs. Europe holds USD 214.3 million and grows 5.21% to USD 356.1 million; it is home to Sartorius, Applikon, Eppendorf and most specialist builders. Asia Pacific starts at USD 173.9 million and climbs to USD 373.4 million, the fastest path at 7.94%, because new enzyme, single-cell protein and microalgae cultivation plants in China and India favour low-shear columns. Latin America adds USD 31.8 million in 2025 and USD 59.6 million in 2035 at 6.48%. The Middle East and Africa start at USD 24.6 million and reach USD 42.4 million at 5.59%. The wildcard is Latin America, where cheap sugar-cane feedstock favours large external-loop fermentation columns and 6.48% growth could prove conservative.

Which end users buy airlift bioreactors, from biopharma lines to wastewater plants?

Biopharmaceutical companies buy 39.6% of airlift bioreactor revenue in 2025, worth about USD 285.8 million, in Douglas Insights figures, followed by academic and research institutes at 24.3% and industrial biotechnology firms at 22.9%. Contract manufacturers hold the remaining 13.2% of airlift spending.

Contract manufacturers take the remaining 13.2%, about USD 95.3 million, and are the fastest-growing buyer at 8.1% a year, since they absorb phage and vector work their clients do not build in-house. Academic and research institutes buy volume, about 5,140 benchtop units, but at low prices. Industrial biotechnology firms buy the big columns: the 142 industrial airlift columns above 8,000 L in our 2025 count sit mostly in enzyme, single-cell protein and wastewater treatment plants. For the ingredients side of fermentation, see our Precision Fermentation Ingredients Market report.

Which GMP rules and contamination standards govern single-use airlift bioreactor bags?

EU GMP Annex 1 on sterile manufacture, fully applicable since 25 August 2024, shapes most airlift bioreactor purchases for medicines in Europe. It pushes buyers towards closed, pre-sterilised systems such as single-use airlift bags. Gamma-irradiated airlift bags fit that rule with little extra validation work.

The European Commission’s EudraLex Volume 4 page lists Annex 1 as fully applicable since 25 August 2024. Annex 1 requires a contamination control strategy, and a closed airlift bag that arrives gamma-irradiated documents easily inside that strategy. Under current good manufacturing practice (cGMP), an airlift bioreactor is qualified as process equipment rather than approved as a product, so the 5 product types carry no separate licence. For non-pharmaceutical airlift columns in microalgae cultivation and wastewater treatment, pressure-equipment and food-contact rules dominate instead.

Are bubble columns and airlift bioreactors counted together in this study?

No: plain bubble columns without a defined riser and downcomer are excluded, which removes an estimated 18.7% of gas-mixed vessel shipments from the airlift bioreactor count and keeps the 2025 total at USD 721.7 million. Rocking bags and stirred tanks are excluded too.

The count includes a vessel when gas injection drives a directed loop: an internal draft tube, a split-cylinder baffle or an external return pipe. Protalix’s disposable plant-cell reactors, which aerate through distributed gas inlets, sit on the boundary and are treated as a captive airlift-type design, not as merchant sales. Shaken flasks, rocking-motion bags and stirred tanks are out of scope, although they appear as substitutes in the pricing and player sections. Lab instrument buyers comparing whole benches can use our Biotechnology Instruments Market report.

What if microalgae and cultivated meat scale faster: how far can the 2035 airlift bioreactor forecast move?

Base-case airlift bioreactor revenue reaches USD 1.31 billion in 2035; the slower case gives USD 1.08 billion and the faster case USD 1.58 billion, depending mainly on how fast single-use and algae columns spread. The range spans USD 493.9 million.

The base case keeps 4.35% unit growth and 1.72% price growth, a 6.14% revenue path. The slower case assumes dense-culture processes stay in stirred tanks and algae projects stall: units grow 2.9% and price 1.2%, giving 4.13% revenue growth and USD 1.08 billion. The faster case assumes cultivated meat pilots convert to production and microalgae cultivation doubles its closed-column base: units grow 5.9% and price 2.1%, an 8.12% path to USD 1.58 billion. A single extra point of annual unit growth adds about USD 131.1 million to the 2035 airlift total. Outside forecasts we read span 4.6% to 9.0% a year, so 6.14% sits slightly under their midpoint.

The bioprocess cycle is the swing factor. Sartorius guided 5% to 9% group growth for 2026 in its 3 February 2026 release; a result at the top of that range would pull airlift orders towards the faster case within 2 years.

Douglas Exclusive: the Airlift Vessel Scale Register

The Airlift Vessel Scale Register is a Douglas Insights model, not an official register, built from 11 sourced inputs. Those are 4 company filings, 2 patent documents, 1 regulator page and 4 published forecast figures, used to allocate the 9,862 airlift bioreactor units of 2025 to five working-volume bands.

The register counts vessels, not litres, and prices each band from list and tender evidence. Its finding is sharp. Benchtop vessels are 52.1% of airlift bioreactor units but only 12.7% of value, while production vessels of 500 to 8,000 L are 7.0% of units and 31.6% of value. The 832 airlift units above 500 L therefore earn USD 344.8 million, almost half the market. For a vendor, winning one 2,000 L plant-cell order is worth roughly 18 benchtop sales.

How the model turns 9,862 airlift bioreactor units into USD 721.7 million?

Our model multiplies 9,862 airlift bioreactor units by an average USD 73,180, which equals USD 721.7 million for 2025; it covers 31 countries in 5 regions and draws on 214 data points. Two cross-checks test the result against supplier filings.

Units come from the five-band register above, which sums exactly to 9,862. Prices come from 46 list and tender observations, weighted by band. The first cross-check compares airlift revenue with Sartorius Bioprocess Solutions sales of EUR 2.87 billion: airlift vessels equal about 22% of that single supplier’s bioprocess sales at 2025 exchange rates, a plausible ratio given that consumables dominate its revenue. The second cross-check compares forecast unit growth of 4.35% with the Sartorius 9.5% constant-currency rise; the airlift rate is less than half, which matches the lag in equipment orders. Regions sum to USD 721.7 million in 2025 and USD 1.31 billion in 2035 within 0.1 million, and the five product types sum to the same 2025 total.

Sources

1. Sartorius AG Preliminary full year results 2025 (2026)
2. Protalix BioTherapeutics FDA approval of Elfabrio announcement (2023)
3. USPTO US patent 10,364,413, large scale disposable bioreactor (2019)
4. European Commission EudraLex Volume 4, Annex 1 (2024)
5. Getinge Getinge to acquire Applikon Biotechnology (2019)
6. Eppendorf SE Annual report 2025, foreword (2026)